-
Mashup Score: 0
Dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0The Potential of Dupilumab Treatment for Prurigo Nodularis - 2 year(s) ago
Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
#AAD2022 news: Dupilumab treatment reduced itch and lesions for #prurigonodularis . Could this become the first FDA approved therapy for the disease? #Dupilumab #Dupixent #dermtwitter https://t.co/2N9ILseFFa
-
-
Mashup Score: 0The Potential of Dupilumab Treatment for Prurigo Nodularis - 2 year(s) ago
Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
Dr. Gil Yosipovitch breaks down the LIBERTY-PN PRIME2 trial, which found that #dupilumab improved itch and lesions in patients with #prurigonodularis #dermtwitter #Dupixent https://t.co/QQsJDUijso
-
-
Mashup Score: 1Pfizer eczema contender beats Dupixent in study, but JAK drug class is still in limbo - MedCity News - 3 year(s) ago
Pfizer has preliminary data showing its experimental drug for atopic dermatitis beat a blockbuster drug from Regeneron Pharmaceuticals in a head-to-head clinical trial. But the future of that drug and others might depend more on an FDA review of safety data for medicines in this class of so-called JAK inhibitors.
Source: MedCity NewsCategories: General Medicine News, Latest HeadlinesTweet-
.@Pfizer #atopicdermatitis drug #abrocitinib looks superior to #Dupixent, according to preliminary data from a head-to-head study. But the bigger hurdle might be FDA scrutiny on the safety of the JAK inhibitor drug class, @frankvinluan reports https://t.co/985KGz1wob $PFE #eczema
-
-
Mashup Score: 0
A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive Phase 3 results involving the monoclonal antibody.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
#Dupilumab Improves Symptoms in Patients with #ChronicSpontaneousUrticaria #Dupixent #Phase3 #Inflammation https://t.co/TngmMamiDR
-
-
Mashup Score: 0Inflammation Review: FDA Approves New Dupixent Dose, Probiotic Mixture Proves Effective for Atopic Dermatitis - 3 year(s) ago
Highlighting the latest inflammation-related news reported across MJH Life Sciences™.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Inflammation Review: #FDA Approves New #Dupixent Dose, Probiotic Mixture Proves Effective for AD, and More https://t.co/A2TtYoJMEq https://t.co/HSf4piHKuO
-
-
Mashup Score: 1FDA Approves New Dose for Dupilumab Pre-filled Pen - 3 year(s) ago
The FDA has approved a single-dose pre-filled pen for dupilumab (Dupixent, Sanofi and Regeneron) for at-home administration.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
The @US_FDA has approved a single-dose pre-filled pen for #dupilumab ( #Dupixent, @sanofi and @Regeneron) for at-home administration. https://t.co/XZVBmF2Fpl https://t.co/sifwauICVA
-
-
Mashup Score: 0
In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
#ICYMI: According to a new @abbvie study of atopic #dermatitis, 71% of the patients who were treated with upadacitinib (#RINVOQ) achieved EASI 75—versus 61% of patients treated with dupilumab (#DUPIXENT). https://t.co/MmniDhnT8S
-
-
Mashup Score: 1
In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
New data from an @abbvie study on atopic #dermatitis demonstrates that upadacitinib (#RINVOQ) was superior to dupilumab (#Dupixent) in regard to primary and secondary endpoints. https://t.co/MmniDh6hKi
-
-
Mashup Score: 0Dupilumab Associated with Improvements in Pediatric Asthma - 4 year(s) ago
The drug has potential to be best-in-class treatment option for children aged 6-11 years with uncontrolled moderate-to-severe asthma.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
Dupilumab (#Dupixent) has the potential to be best-in-class treatment option for children aged 6-11 years with uncontrolled moderate-to-severe #asthma. https://t.co/i7D2yFv7uA
-
BREAKING: The Food and Drug Administration accepted for Priority Review a supplemental biologics license application for #dupilumab (#Dupixent) for the treatment of adults and patients 12 years and older with eosinophilic esophagitis. @sanofi @Regeneron https://t.co/ie6J2WliTj